Therefore, based on the close connection of serum sPD-1 levels with HBV-related HCC, it, speculatively, holds promise to examine the potential of serum sPD-1 as a noninvasive predictive biomarker for the immunotherapy of HCC through targeting PD-1 pathway. Here, PDCD1 is linked to hepatocellular carcinoma.